Azitra, Inc. (AZTR)

ASE – Real Time Price. Currency in USD

0.17

+0.00 (0.78%)

At close: Jun 26, 2026, 4:00 PM EDT

0.16

-0.01 (-3.17%)

After-hours: Jun 26, 2026, 7:55 PM EDT

17.06.2026

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond.

04.06.2026

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally scheduled for and convened on June 4, 2026, has been adjourned until June 15, 2026, at 11:00 a.m.

27.05.2026

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming 2026 annual meeting of stockholders (the "2026 Annual Meeting") scheduled for June 4, 2026 at 11:00 a.m.

13.05.2026

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2026, and provided a business update.

06.05.2026

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndrome BRANFORD, Conn.

28.04.2026

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the presentation of new preclinical data from its ATR-01 program at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy ("ASGCT 2026").

20.03.2026

Why Are Shares Of Azitra Rising?

Azitra's spike is being fueled by a securities purchase agreement with healthcare-focused institutional investors for gross proceeds of up to $31.4 million, with Series B and C warrants exercisable at $0.123 per share and Series A convertible preferred priced at $1,000 per share.

Videos

No Data

There is no data to display

Press releases

17.06.2026

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

04.06.2026

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

27.05.2026

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

13.05.2026

Azitra, Inc. (AZTR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Azitra, Inc. (AZTR)

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Why Are Shares Of Azitra Rising?

Videos

No Data

Press releases

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Why Are Shares Of Azitra Rising?

Videos

No Data

Press releases

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Search stocks

Azitra, Inc. (AZTR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Azitra, Inc. (AZTR)

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Why Are Shares Of Azitra Rising?

Videos

No Data

Press releases

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Why Are Shares Of Azitra Rising?

Videos

No Data

Press releases

Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond

Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting

Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting

Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates